Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 909,000 shares, an increase of 72.4% from the December 31st total of 527,200 shares. Currently, 8.3% of the company’s shares are short sold. Based on an average daily volume of 3,030,000 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $7.00 target price on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Stock Performance

Shares of Windtree Therapeutics stock opened at $0.13 on Friday. The stock has a 50 day moving average of $0.33 and a 200 day moving average of $2.85. The firm has a market capitalization of $1.44 million, a price-to-earnings ratio of -0.01 and a beta of 0.57. Windtree Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $14.75.

Windtree Therapeutics (NASDAQ:WINT) last released its quarterly earnings results on Tuesday, November 26th. The company reported ($4.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.27) by ($1.96). Analysts forecast that Windtree Therapeutics will post -5.66 EPS for the current year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.